Brad Rosbrook

7.9k total citations · 4 hit papers
87 papers, 4.4k citations indexed

About

Brad Rosbrook is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Brad Rosbrook has authored 87 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 32 papers in Cancer Research. Recurrent topics in Brad Rosbrook's work include Renal cell carcinoma treatment (44 papers), Renal and related cancers (23 papers) and Prostate Cancer Treatment and Research (22 papers). Brad Rosbrook is often cited by papers focused on Renal cell carcinoma treatment (44 papers), Renal and related cancers (23 papers) and Prostate Cancer Treatment and Research (22 papers). Brad Rosbrook collaborates with scholars based in United States, France and Spain. Brad Rosbrook's co-authors include Jamal Tarazi, Sinil Kim, Brian I. Rini, Thomas E. Hutson, Andrew J. Armstrong, Robert J. Motzer, Connie Chen, Bernard Escudier, Neal D. Shore and Taro Iguchi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Brad Rosbrook

87 papers receiving 4.3k citations

Hit Papers

ARCHES: A Randomized, Phase III Study of Andro... 2013 2026 2017 2021 2019 2013 2018 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
    2019 686 citations Andrew J. Armstrong, Brad Rosbrook et al. Journal of Clinical Oncology profile →
  2. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    2013 542 citations Robert J. Motzer, Bernard Escudier et al. The Lancet Oncology profile →
  3. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
    2018 274 citations Michael B. Atkins, Elizabeth R. Plimack et al. The Lancet Oncology profile →
  4. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
    2022 169 citations Andrew J. Armstrong, Brad Rosbrook et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brad Rosbrook United States 27 3.2k 1.8k 1.5k 1.4k 457 87 4.4k
Umberto Basso Italy 35 1.7k 0.5× 1.0k 0.6× 2.1k 1.4× 736 0.5× 283 0.6× 236 4.7k
Adolfo Favaretto Italy 31 2.2k 0.7× 780 0.4× 1.7k 1.1× 357 0.3× 231 0.5× 136 3.7k
Peter Venner Canada 40 4.8k 1.5× 1.9k 1.1× 3.3k 2.2× 1.5k 1.1× 711 1.6× 116 8.4k
Francisco Vera-Badillo Canada 27 1.6k 0.5× 754 0.4× 3.4k 2.2× 1.2k 0.9× 414 0.9× 76 5.5k
Rana R. McKay United States 36 3.0k 0.9× 1.3k 0.8× 2.3k 1.5× 1.2k 0.9× 421 0.9× 416 5.0k
Alicia K. Morgans United States 29 1.9k 0.6× 557 0.3× 1.1k 0.7× 429 0.3× 422 0.9× 202 3.4k
Anders Mellemgaard Denmark 41 4.6k 1.4× 1.9k 1.1× 4.1k 2.7× 1.1k 0.8× 220 0.5× 144 7.6k
James T. Symanowski United States 28 3.1k 1.0× 680 0.4× 1.4k 0.9× 451 0.3× 484 1.1× 172 4.8k
Scott North Canada 39 5.5k 1.7× 2.6k 1.4× 2.8k 1.8× 2.2k 1.6× 1.2k 2.7× 193 7.6k
Marlo Whitehead Canada 26 2.7k 0.9× 930 0.5× 2.4k 1.6× 599 0.4× 329 0.7× 82 4.3k

Countries citing papers authored by Brad Rosbrook

Since Specialization
Citations

This map shows the geographic impact of Brad Rosbrook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Rosbrook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Rosbrook more than expected).

Fields of papers citing papers by Brad Rosbrook

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Rosbrook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Rosbrook. The network helps show where Brad Rosbrook may publish in the future.

Co-authorship network of co-authors of Brad Rosbrook

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Rosbrook. A scholar is included among the top collaborators of Brad Rosbrook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Rosbrook. Brad Rosbrook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rini, Brian I., Michael B. Atkins, Toni K. Choueiri, et al.. (2023). Plain Language Summary Looking at How Long Side Effects Last After Treatment with Axitinib is Stopped in People with Advanced Renal Cell Carcinoma. Future Oncology. 19(40). 2623–2629. 1 indexed citations
2.
Rini, Brian I., Michael B. Atkins, Toni K. Choueiri, et al.. (2021). Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 19(5). e306–e312. 13 indexed citations
3.
Quinn, David I., Chi‐Fai Ng, Enrique Grande, et al.. (2021). ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. ESMO Open. 6(3). 100105–100105. 6 indexed citations
4.
Armstrong, Andrew J., Ping Lin, Bertrand Tombal, et al.. (2020). Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. European Urology. 78(3). 347–357. 101 indexed citations
5.
Bracarda, Sergio, Aristotelis Bamias, Jochen Casper, et al.. (2019). Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. Clinical Genitourinary Cancer. 17(3). e689–e703. 11 indexed citations
6.
Gross‐Goupil, Marine, Tae‐Geon Kwon, Masatoshi Eto, et al.. (2018). Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of Oncology. 29(12). 2371–2378. 176 indexed citations
7.
Atkins, Michael B., Elizabeth R. Plimack, Igor Puzanov, et al.. (2018). Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. The Lancet Oncology. 19(3). 405–415. 274 indexed citations breakdown →
8.
Rini, Brian I., Thomas E. Hutson, Robert A. Figlin, et al.. (2018). Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clinical Genitourinary Cancer. 16(4). 298–304. 42 indexed citations
9.
Sheng, Xinan, Feng Bi, Ying Cheng, et al.. (2017). First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of data from a phase III trial. Annals of Oncology. 28. x82–x82. 2 indexed citations
10.
Claret, Laurent, Jenny Zheng, François Mercier, et al.. (2016). Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer Chemotherapy and Pharmacology. 78(3). 605–610. 4 indexed citations
11.
Atkins, M.B., Elizabeth R. Plimack, Igor Puzanov, et al.. (2016). Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results. Annals of Oncology. 27. vi266–vi266. 26 indexed citations
12.
Hutson, Thomas E., С Х Аль-Шукри, V.P. Stus, et al.. (2016). Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clinical Genitourinary Cancer. 15(1). 72–76. 49 indexed citations
13.
Rini, Brian I., Yoshihiko Tomita, Bohuslav Melichar, et al.. (2016). Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 14(6). 499–503. 37 indexed citations
14.
Escudier, Bernard, Brian I. Rini, Robert J. Motzer, et al.. (2015). Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 13(4). 328–337.e3. 29 indexed citations
15.
Rini, Brian I., Bernard Escudier, Hariharan Subramanian, et al.. (2015). Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 13(6). 540–547.e7. 23 indexed citations
16.
Martin, Lainie P., Mark Kozloff, Roy S. Herbst, et al.. (2012). Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 107(8). 1268–1276. 21 indexed citations
17.
Fruehauf, John P., Jose Lutzky, David H. McDermott, et al.. (2011). Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. Clinical Cancer Research. 17(23). 7462–7469. 93 indexed citations
18.
Trask, Peter C., Andrew G. Bushmakin, Joseph C. Cappelleri, et al.. (2011). Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. Journal of Cancer Survivorship. 5(3). 255–262. 5 indexed citations
19.
Dutcher, Janice P., G. R. Hudes, Walter M. Stadler, et al.. (2008). Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. Journal of Clinical Oncology. 26(15_suppl). 5127–5127. 29 indexed citations
20.
Rubenstein, Laurence Z., et al.. (1988). Improved survival for frail elderly inpatients on a geriatric evaluation unit (GEU): Who benefits?. Journal of Clinical Epidemiology. 41(5). 441–449. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Umberto Basso Breakdown of academic impact, for papers by Adolfo Favaretto Breakdown of academic impact, for papers by Peter Venner Breakdown of academic impact, for papers by Francisco Vera-Badillo Breakdown of academic impact, for papers by Rana R. McKay Breakdown of academic impact, for papers by Alicia K. Morgans Breakdown of academic impact, for papers by Anders Mellemgaard Breakdown of academic impact, for papers by James T. Symanowski Breakdown of academic impact, for papers by Scott North Breakdown of academic impact, for papers by Marlo Whitehead
Rankless by CCL
2026